Reclast (ZOL446, zoledronic acid)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Paget's Disease of the Bone
Conditions
Paget's Disease of the Bone, Hypocalcemia
Trial Timeline
May 1, 2008 → Nov 1, 2012
NCT ID
NCT00668200About Reclast (ZOL446, zoledronic acid)
Reclast (ZOL446, zoledronic acid) is a approved stage product being developed by Novartis for Paget's Disease of the Bone. The current trial status is completed. This product is registered under clinical trial identifier NCT00668200. Target conditions include Paget's Disease of the Bone, Hypocalcemia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00668200 | Approved | Completed |
Competing Products
5 competing products in Paget's Disease of the Bone
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements | Novartis | Phase 3 | 77 |
| Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid | Novartis | Phase 3 | 77 |
| Zoledronic Acid | Novartis | Approved | 85 |
| Zoledronic acid | Novartis | Approved | 85 |
| alendronate | Organon | Phase 3 | 72 |